IGFBP3 and metabolic dysfunction-associated steatohepatitis: Recent reports suggest that IGF-1 biodisponibility might be decreased during disease progression toward NASH and liver fibrosis and advance IGF-1/intact IGFBP3 ratio as a fibrosis predictor (54).